Neoadjuvant LTX-315 plus pembrolizumab for resectable melanoma
Part of Cancer, Skin clinical trials.
This trial tests a combination of two drugs (LTX-315 and pembrolizumab) given before surgery to shrink melanoma that is stage III or IV (M1a) and can be removed. The goal is to see if this approach works better than surgery alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have stage III or IV (M1a) melanoma that can be fully removed by surgery.
- You have at least one melanoma bump under the skin or in a lymph node that is 3 cm or smaller and can be injected.
- You must be willing to have extra biopsies and donate tissue samples, and be healthy enough for surgery.
- You cannot have had prior immunotherapy (like PD-1/CTLA-4 drugs) for melanoma, and you cannot have active autoimmune disease or certain other conditions.
- Your blood counts (hemoglobin, neutrophils, platelets) and organ function (liver, kidney) must be within specified ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called LNS8801, alone or with pembrolizumab, for people with advanced melanoma that has stopped responding to prior treatments, especially anti-PD-1 therapy.
This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.
This trial tests whether giving pembrolizumab (Keytruda) before surgery helps people with a certain type of advanced melanoma (stage IIb/c). The goal is to see if this treatment can improve outcomes before the tumor is removed.
This trial tests a combination of daily low-dose cyclophosphamide (a chemotherapy pill) and pembrolizumab (an immunotherapy) in people with advanced melanoma that has stopped responding to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests a combination of three immunotherapy drugs (cemiplimab, fianlimab, and ipilimumab) before surgery in people with melanoma that can be surgically removed. The goal is to see if this treatment helps shrink the cancer and improves outcomes.
This study tests a new approach for advanced melanoma that is not responding to standard immunotherapy (like pembrolizumab). It combines a targeted injection directly into the tumor (L19IL2, L19TNF, or both) with pembrolizumab. The goal is to see if this combination can shrink tumors and help the immune system fight the cancer.
Hear when a new Melanoma Stage IIIB-IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.